Opinion|Videos|April 7, 2025
Cilta-cel vs. Ide-cel: Key Data Updates and Clinical Decision-Making in R/R MM
Author(s)Surbhi Sidana, MD, Peter Voorhees, MD
Experts discuss how they decide between utilizing cilta-cel vs ide-cel in multiple myeloma, considering factors like disease characteristics, patient factors, and product differences, while reviewing the final progression-free survival (PFS) analysis from the KarMMA-3 study with ide-cel and key takeaways from the ASH 2024 update on minimal residual disease (MRD) negativity rates from CARTITUDE-4 with cilta-cel and its impact on clinical practice.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How are you deciding between utilizing cilta-cel vs ide-cel, and what factors (disease, patient, and/or product) impact that decision?
- KarMMA-3 with ide-cel also recently reported its final PFS analysis. What were some highlights of this data, and what areyour impressions so far?
- There was a recent update from ASH 2024 regarding the MRD negativity rates from CARTITUDE-4 with cilta-cel; what were some of your key takeaways, and have the data impacted your clinical practice?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
Data from EXCALIBER-RRMM supported FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in R/R multiple myeloma.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC
4
Five Under 5: Top Oncology Videos for the Week of 8/9
5